Atossa Therapeutics Advances Product Development Programs with Multiple Key Hires in Clinical, Regulatory, and Chemistry Manu...
July 08 2020 - 9:30AM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage
biopharmaceutical company seeking to discover and develop
innovative medicines in areas of significant unmet medical need
with a current focus on breast cancer and COVID-19, announced it
has hired key personnel in clinical, regulatory and chemistry
manufacturing and controls (CMC). The new hires include Heather
Fraser, Ph.D., as vice president of clinical, regulatory and CMC;
Natalie Farris, MS, as senior director of CMC; and Devon Payne as
director of clinical operations.
“Hiring of these talented and accomplished individuals will help
accelerate the advancement of our development pipeline, which
includes programs in breast cancer and COVID-19,” commented Steven
Quay, M.D., Ph.D., president and CEO of Atossa. “We welcome
Heather, Natalie and Devon to Atossa and look forward to their
important contributions as we execute on our value-creation
strategy.”
B. Heather Fraser, Ph.D., joins Atossa from Cerecor Inc., where
she served as vice president of clinical operations and program
management for eight years. She has more than 20 years of biotech
experience, including positions of increasing responsibility at
Cerecor Inc., Anthera Pharmaceuticals, and CV Therapeutics. She
received her B.S. in Zoology from the University of British
Columbia, an M.S. in Pharmaceutical Sciences from the University of
Montana, and her Ph.D. in Pharmacology from the University of
Alberta. She also completed a post-doctorate fellowship at Johns
Hopkins University.
Natalie Farris, MS, has more than 18 years of experience in the
vaccines and biopharmaceutical industries, most recently at
GlaxoSmithKline, in vaccines, where she served as senior manager of
regulatory affairs and CMC, and at Cerecor Inc., in
biopharmaceuticals, where she served as senior director of CMC.
Prior to these, she held positions at various well-known companies,
including Vanda Pharmaceuticals Inc., Esai, Inc., Shire
Pharmaceutical, Inc. and AVI Biopharma. She earned both her B.S. in
Chemistry and M.S. in Geochemistry from the University of
Delaware.
Devon Payne has worked in the biopharma industry for more than
17 years in a variety of areas, including clinical project
management and research. Most recently, Ms. Payne served as
associate director of clinical operations at Omeros Corporation.
Prior, she served in clinical and research roles at Icon Clinical
Research, Alere, Inc. (now part of Abbott), Proteogenix, Inc., and
others. She received her B.A. in Psychology from California State
University, Long Beach.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical
company seeking to discover and develop innovative medicines in
areas of significant unmet medical need with a current focus on
breast cancer and COVID-19. For more information, please visit
www.atossatherapeutics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between
interim and final clinical results, whether in vitro test results
will also be achieved in in vivo studies, including human clinical
studies, actions by and interactions with the FDA, the outcome or
timing of regulatory approvals needed by Atossa including those
needed to commence human clinical studies of AT-H201 and AT-301,
lower than anticipated rate of patient enrollment, estimated market
size of drugs under development, the safety and efficacy of
Atossa’s products, performance of clinical research organizations
and investigators, obstacles resulting from proprietary rights held
by others such as patent rights, and other risks detailed from time
to time in Atossa’s filings with the Securities and Exchange
Commission, including without limitation its periodic reports on
Form 10-K and 10-Q, each as amended and supplemented from time to
time.
Company Contact: Atossa Therapeutics, Inc. Kyle Guse, CFO and
General Counsel Office: (866) 893-4927 kyle.guse@atossainc.com
Investor Relations Contact: Core IROffice: (516)
222-2560ir@atossainc.com
Source: Atossa Therapeutics, Inc.
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2023 to Apr 2024